Analysts are on the Bearish side about Mylan N.V. (NASDAQ:MYL) this week.

Mylan N.V. (NASDAQ:MYL) LogoInvestors sentiment increased to 2 in 2018 Q2. Its up 1.00, from 1 in 2018Q1. It improved, as 2 investors sold Mylan N.V. shares while 0 reduced holdings. 3 funds opened positions while 1 raised stakes. 356,551 shares or 87.07% more from 190,596 shares in 2018Q1 were reported.
Gulf Intll Bank & Trust (Uk) Limited has invested 0.08% in Mylan N.V. (NASDAQ:MYL). Vantage Inv Advsr Limited Com owns 337 shares. Whittier Trust, California-based fund reported 142,248 shares. Whittier Trust Of Nevada, a Nevada-based fund reported 33,450 shares. 12 are owned by Gemmer Asset Management Ltd Llc.

Mylan N.V. (NASDAQ:MYL) Ratings Coverage

Among 7 analysts covering Mylan (NASDAQ:MYL), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Mylan had 10 analyst reports since August 9, 2018 according to SRatingsIntel. On Friday, October 5 the stock rating was downgraded by Mizuho to “Neutral”. As per Tuesday, November 6, the company rating was maintained by Citigroup. Bank of America upgraded it to “Buy” rating and $42 target in Tuesday, November 6 report. The company was maintained on Thursday, August 9 by Citigroup. The firm has “Equal-Weight” rating given on Tuesday, October 9 by Morgan Stanley. RBC Capital Markets upgraded the shares of MYL in report on Monday, August 13 to “Outperform” rating. The rating was maintained by RBC Capital Markets on Tuesday, November 6 with “Outperform”. The stock of Mylan N.V. (NASDAQ:MYL) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, November 6. The stock of Mylan N.V. (NASDAQ:MYL) earned “Outperform” rating by Raymond James on Thursday, August 9. Argus Research upgraded the shares of MYL in report on Thursday, November 15 to “Buy” rating. Below is a list of Mylan N.V. (NASDAQ:MYL) latest ratings and price target changes.

15/11/2018 Broker: Argus Research Old Rating: Hold New Rating: Buy Upgrade
06/11/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $36 New Target: $39 Maintain
06/11/2018 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $51 New Target: $50 Maintain
06/11/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $48 New Target: $44 Maintain
06/11/2018 Broker: Bank of America Old Rating: Neutral New Rating: Buy Old Target: $44 New Target: $42 Upgrade
09/10/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Old Target: $46 New Target: $36 Downgrade
05/10/2018 Broker: Mizuho Old Rating: Buy New Rating: Neutral Downgrade
13/08/2018 Broker: RBC Capital Markets Old Rating: Sector Perform New Rating: Outperform Old Target: $53 Upgrade
09/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $50 New Target: $48 Maintain
09/08/2018 Broker: Raymond James Old Rating: Strong Buy New Rating: Outperform Downgrade

The stock decreased 4.05% or $1.29 during the last trading session, reaching $30.55. About 5.85 million shares traded or 17.06% up from the average. Mylan N.V. (NASDAQ:MYL) has risen 12.23% since December 8, 2017 and is uptrending. It has underperformed by 3.39% the S&P500.

Mylan N.V., together with its subsidiaries, develops, licenses, makes, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company has market cap of $15.75 billion. The firm operates through three divisions: North America, Europe, and Rest of World. It has a 29.15 P/E ratio. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

More notable recent Mylan N.V. (NASDAQ:MYL) news were published by: Nasdaq.com which released: “3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 – Nasdaq” on November 30, 2018, also Seekingalpha.com with their article: “Mylan lower after FDA warning – Seeking Alpha” published on November 20, 2018, Nasdaq.com published: “Even Following the Latest Surge, Mylan Stock Has Plenty of Room to Grow – Nasdaq” on November 08, 2018. More interesting news about Mylan N.V. (NASDAQ:MYL) were released by: Seekingalpha.com and their article: “FDA OKs Theravance and Mylan’s COPD med revefenacin – Seeking Alpha” published on November 09, 2018 as well as Fool.com‘s news article titled: “Here’s Why Momenta Pharmaceuticals Jumped 18% on Friday – The Motley Fool” with publication date: December 07, 2018.

Mylan N.V. (NASDAQ:MYL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.